![DSpace logo](/jspui/image/logo.gif)
Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13503
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gaikwad, Anil Bhanudas | - |
dc.date.accessioned | 2023-12-22T10:48:20Z | - |
dc.date.available | 2023-12-22T10:48:20Z | - |
dc.date.issued | 2023-02 | - |
dc.identifier.uri | https://www.frontiersin.org/articles/10.3389/fphar.2023.1053814/full | - |
dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13503 | - |
dc.description.abstract | Antiviral drugs such as Remdesivir (Veklury), Nirmatrelvir with Ritonavir (Paxlovid), Azvudine, and Molnupiravir (Lagevrio) can reduce the risk for severe and fatal Coronavirus Disease (COVID)-19. Although chronic kidney disease is a highly prevalent risk factor for severe and fatal COVID-19, most clinical trials with these drugs excluded patients with impaired kidney function. Advanced CKD is associated with a state of secondary immunodeficiency (SIDKD), which increases the susceptibility to severe COVID-19, COVID-19 complications, and the risk of hospitalization and mortality among COVID-19 patients. The risk to develop COVID-19 related acute kidney injury is higher in patients with precedent CKD. Selecting appropriate therapies for COVID-19 patients with impaired kidney function is a challenge for healthcare professionals. Here, we discuss the pharmacokinetics and pharmacodynamics of COVID-19-related antiviral drugs with a focus on their potential use and dosing in COVID-19 patients with different stages of CKD. Additionally, we describe the adverse effects and precautions to be taken into account when using these antivirals in COVID-19 patients with CKD. Lastly, we also discuss about the use of monoclonal antibodies in COVID-19 patients with kidney disease and related complications. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Frontiers | en_US |
dc.subject | Pharmacy | en_US |
dc.subject | Antiviral drugs | en_US |
dc.subject | Remdesivir (Veklury) | en_US |
dc.subject | Ritonavir (Paxlovid) | en_US |
dc.subject | COVID-19 | en_US |
dc.title | How to use COVID-19 antiviral drugs in patients with chronic kidney disease | en_US |
dc.type | Article | en_US |
Appears in Collections: | Department of Pharmacy |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.